Therefore, it is necessary to develop non-invasive or minimally invasive detection methods, such as using circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in blood or other fluids, to predict the clinical response of anti-PD-1/PD-L1 therapy in cancer (143). Here, CD274 is linked to neoplasm.